What is AlonSource Group?
Alon Source Group is a prominent developer and provider of amniotic tissue allografts, dedicated to advancing patient care through innovative regenerative medicine solutions. The company's product portfolio encompasses amniotic membrane allografts for wound management and allograft bone for orthopedic applications, serving critical needs in sports medicine, orthopedics, spine, urology, and OB/GYN specialties. Alon Source Group actively engages with surgeons to refine its offerings and pioneer new technologies aimed at improving patient outcomes.
How much funding has AlonSource Group raised?
AlonSource Group has raised a total of $266K across 2 funding rounds:
Debt
$150K
Debt
$116K
Debt (2020): $150K with participation from PPP
Debt (2021): $116K led by PPP
Key Investors in AlonSource Group
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for AlonSource Group?
The substantial backing and strategic investment indicate AlonSource Group is poised for significant expansion. This capital infusion is likely to fuel further research and development into novel regenerative therapies, enhance manufacturing capabilities, and broaden market reach. The company's focus on improving patient outcomes through advanced allograft technology positions it for continued growth and leadership in the competitive regenerative medicine landscape.
See full AlonSource Group company page
